| 摘要 |
The present invention provides novel compounds, which comprise FLINT complexed with a divalent metal cation, pharmaceutical formulations thereof, methods for reducing and/or inducing aggregation of FLINT, and methods of using such compounds for treating or preventing diseases that may be related to the FasL/Fas interaction. |
